Andere Sprachen Revolution Medicines, Inc.

Aktien

A2PYWG

US76155X1000

RVMD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
35.96 ^USD	+1.78%		+2.98%	+25.38%

12.04.	REVOLUTION MEDICINES, INC. : Oppenheimer bekräftigt seine Kaufempfehlung	ZM
12.04.	REVOLUTION MEDICINES, INC. : Needham & Co. bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures -2-	11.04.
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	09.04.
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	08.04.
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs	05.04.
Revolution Medicines to Participate in Upcoming Investor Conferences	04.04.
Aethon Therapeutics, Inc. Announces Collaboration with Revolution Medicines, Inc. to Discover and Develop Novel Aethon Antibody Programs	04.04.
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024	28.03.
Revolution Medicines Insider Sold Shares Worth $805,652, According to a Recent SEC Filing	13.03.
Revolution Medicines Files Mixed-Securities Shelf	05.03.
Revolution Medicines Q4 Net Loss Widens, Revenue Drops	26.02.
Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Earnings Flash (RVMD) REVOLUTION MEDICINES Posts Q4 Revenue $742,000, vs. Street Est of $1.2M	26.02.
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress	26.02.
Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024	26.02.
Revolution Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.02.
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024	20.02.
Revolution Medicines to Participate in Upcoming Investor Conferences	01.02.
North American Morning Briefing : Boeing Drags -2-	08.01.
Revolution Medicines Insider Sold Shares Worth $387,884, According to a Recent SEC Filing	04.01.
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Revolution Medicines, Inc.

Aktien

A2PYWG

US76155X1000

RVMD

Andere Sprachen

Filter